Changzhou Pharmaceutical Factory (CPF) was founded in 1949 and is now a core enterprise of Shanghai Pharma Holding Group. CPF has 2 production sites, respectively located in Changzhou, Jiangsu and Rudong, Nantong. It is a comprehensive pharmaceutical manufacturer engaged in production of APIs and FDFs, and has a good share in domestic marekt and abroad. CPF achieved sales revenue of 1.52 billion RMB in 2023. Its parent company, SPH is one of the worldwide top 500 enterprises. CPF has a complete quality management system, all the workshops in both manufacturing sites conform to GMP requirement, since 1984 CPF has passed the US FDA for more than 10 times, the company's FDF facility has passed the EU GMP and FDA inspections as well.
Main API products: Rosuvastatin calcium, Ticagrelor, Ezemibe, Hydrochlorothiazide, Doxycycline Hyclate, Captopril, Rivaroxaban, Apixaban, LCZ696, Tofacatib, Lenalidomide, Finerenone, Obeticholic acid, Sugammadex sodium, Abrocitinib, Baloxavir Maboxil, Eltrombopag, Elagolix, Relugolix, Rimegepant, Venetoclas, Vericiguat, Niraparib, Ruxolitinib.
Pipeline API products: Deucravacitinib, Abemaciclib, Darolutamide, Resmetirom, Etrasimod, Vibegron, Semaglutide, Tirzepatide
Year of Establishment:
2001
Total Assets(USD):
choose not to disclose
Total Number of Staff:
less than 10 person
Main Competitive Advantages:
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
R&D capacity:
Annual Turnover(USD):
choose not to disclose
Main Sales Markets:
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Other Competitive Advantages:
Patents and Copyrights:
Six years of qualification
Audited Supplier
Pharma Sources Insight January 2025
